However, as the below indicates -- pembrolizumab will. . . reign supreme. And this is a reminder of just how stellar Merck has become, a decade on -- since the days of the 2009 Schering-Plough yard sale. I've scarcely written a reproachful word on the topic, in over a year. Add to that, that Merck's chairman was a lone first voice to stand up to Trump's open Charlottesville racism, and this is a company to be admired, as world class -- across all industries again [as it was in the 1970s and 1980s].
Here's a bit, from Forbes, on Friday:
. . . .Keytruda will be the best-selling drug in the world by 2023, according to a report on Friday from the research firm GlobalData.
GlobalData projected annual sales of Keytruda to hit $22.2 billion by 2025.
“Emerging as an effective treatment for a range of cancers, Keytruda has developed into Merck & Co’s biggest product,” GlobalData pharma analyst Keshalini Sabaratnam said in a statement. . . .
Congrats go out to Mr. Frazier, and the team. Truly well-deserved. A model for American multi-nationals, indeed. Onward, to a mountain bike ride by the lake. . . .
नमस्ते
5 comments:
Slightly off topic, but do you know if Merck still maintains its investment in Moderna?
Indeed it does — see this news item at BioPharmaDive — from about three weeks ago (describing the vaccines relationship):
https://www.biopharmadive.com/news/moderna-marks-progress-toward-goal-of-coaxing-medicine-from-bodys-cells/562743/
Namaste....
It wouldn’t surprise me if Merck sold some of its stake — but not all, after the IPO:
https://shearlingsplowed.blogspot.com/2018/11/various-tea-leaves-to-be-read-on-mercks.html
Thank you for the response.
To be fair, since the investment was immaterial to massive Merck, and was less than 5% of Moderna at IPO launch, there may never be another public filing setting out Merck’s downdated holdings.
But it seems logical that Merck kept at least some of it, as a “rainy day” money / hedge position, if nothing else.
Namaste.
Post a Comment